الفهرس 
Prognostic implication of MYC/BCL2 in patients with diffuse large B-Cell NHL
ContentsOnly 14 pages are availabe for public view
 |  | from | 244 |  |  |
| | | from | 244 | | |
Abstract
Background: non-Hodgkin lymphoma is the 7th most commonly diagnosed cancer among men and women; diffuse large B-cell lymphoma represents 32% of non-Hodgkin’s lymphoma cases. In Egypt, NHL is the 5th most common cancer. Aim: to study the frequency of C-MYC/BCL-2 in adult Diffuse Large B Cell Lymphoma (DLBCL) patients presented to Egyptian National Cancer Institute and Tanta Cancer Center and to classify these patients into GC & ABC according to CD-10, BCL-6 and MUM-1. And to assess the correlation between the presence of these prognostic markers and treatment outcome, overall survival and disease free survival Methods: this is a prospective study that included 100 adult patients with newly diagnosed and pathological confirmed Diffuse Large-B Cell Lymphoma (CD20+) who were treated by R- CHOP regimen presenting to Egyptian National Cancer Institute and Tanta Cancer Center between the period of January 2014 and December 2016 and followed up till January 2019. Detection of CD10, BCL6, MUM1, C-MYC and BCL2 by immunohistochemistry as prognostic markers. The following data were studied: patient’s characteristics, treatment outcome and prospective overall Results: Age ranged from 25-68 years (median age was 49 years). Male cases were 52(52%) while female were 48(48%). Most of our patients presented with advanced stage (42% stage III and 25% stage IV) and (45%) of patients had bulky disease. Extra nodal sites were detected in 42% and patients presented with B-symptoms were 59%. The revised IPI showed that 4% had low IPI, 63% had intermediate IPI and 33% had high IPI. Chemotherapy response showed that 78 patients (78%) had CR response. CR response was lower in the double hit group (45%) while there is no difference between germinal center and non- germinal center groups. Only 21 patients were relapsed